

Press Release

Heerlen (NL), 27 July 2021

Royal DSM
media.contacts@dsm.com
www.dsm.com

22E

DSM acquires next-generation eubiotics platform start-up

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has acquired Midori USA, Inc. ("Midori"), a biotechnology start-up with a novel precision platform developing breakthrough targeted eubiotics that improve the health and environmental impact of animals. DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US\$63m.

Boston Massachusetts-based Midori has developed a technology platform that identifies glycans derived from natural food sugars that can precisely modulate how the gut microbiome functions in animals. These glycans provide an effective and consistent impact on animal gut health, leading to improved nutrient utilization from feed and improved animal health. Such eubiotics can reduce the environmental footprint of animal farming and support the accelerated replacement of antibiotics in animal feed.

The use of eubiotics has grown significantly as farming practices shift to become more sustainable and along with the need to provide antibiotic alternatives. Midori's platform is highly synergetic with DSM's bioscience capability and current eubiotics portfolio, which was further strengthened through the acquisition of Biomin (as part of the Erber Group).

DSM will launch its first targeted glycan - Symphiome™ - later this year. This unique eubiotic will be the first product from DSM's collaboration with Midori, leveraging functional modulation of the gut microbiome to improve the gut health, feed efficiency and welfare of poultry, while reducing the use of antibiotics and lowering the environmental emissions of poultry farming. Symphiome™ will be the second novel mode of action eubiotic product that DSM will bring to the market after the successful launch of Balancius®, a breakthrough innovation that improves the overall digestive health of animals.

DSM – Bright Science. Brighter Living.™

Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Or find us on:    

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:

DSM Media Relations
Lieke de Jong
tel. +31 (0) 45 5782420
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
e-mail investor.relations@dsm.com